All In Biotech

Drug Trial Radar · NCT07029555

An Ascending Dose Study of PIT565 in Participants With Rheumatoid Arthritis

A Phase Ib, Open-label, Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of PIT565 in Participants With Rheumatoid Arthritis (RA)

Last checked: Nov 20, 2026Latest source record: Jun 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

57

Planned (sponsor's estimate)

Start

Jun 12, 2025

Primary completion

May 15, 2028

Study completion May 16, 2028

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Jun 19, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to determine the safety, tolerability, and pharmacokinetics of PIT565, in participants with rheumatoid arthritis (RA).

Conditions

  • Rheumatoid Arthritis

Interventions

  • PIT565Biological

    Study treatment will be provided in vials as open-label participant specific supply.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: 6 months

Locations

16 sites in 9 countries. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    CABA, Argentina

  • Novartis Investigative Site

    Pilar, Buenos Aires, Argentina

  • Novartis Investigative Site

    Sofia, Bulgaria

  • Novartis Investigative Site

    Beijing, China

  • Novartis Investigative Site

    Beijing, China

  • Novartis Investigative Site

    Brest, France

  • Novartis Investigative Site

    Le Kremlin-Bicêtre, France

  • Novartis Investigative Site

    Paris, France

  • Novartis Investigative Site

    Mainz, Germany

  • Novartis Investigative Site

    Jena, Thuringia, Germany

  • Novartis Investigative Site

    Szeged, Hungary

  • Novartis Investigative Site

    Leiden, South Holland, Netherlands

  • Novartis Investigative Site

    Bucharest, Romania

  • Novartis Investigative Site

    Cluj-Napoca, Cluj, Romania

  • Novartis Investigative Site

    Barcelona, Spain

  • Novartis Investigative Site

    Santiago Compostela, A Coruna, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.